HIGHLIGHTS
- who: Seijong Kim from the Kyorin, Japan have published the research work: Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer, in the Journal: (JOURNAL)
- how: In this study anastomosis site leakage was significantly higher in patients with discontinuation dates shorter than 5 weeks and there was no significant difference between the two groups when compared based on a 4 or 6-week discontinuation interval.
- future: Prospective studies from multi-centers should be conducted to confirm the study results.
SUMMARY
From January 2010 to December 2020 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.